无需基因操作的自然选择CD7 CAR-T细胞治疗T-ALL/LBL:首次人体1期临床试验
本研究采用无需基因操作的自然选择CD7 CAR-T(NS7CAR)治疗20例复发/难治性T-ALL(14例)和T-LBL(6例)。19例在28天内达骨髓微小残留病阴性完全缓解,9例中5例达髓外完全缓解。中位随访142.5天后,14例后续接受移植且无复发;未移植6例中4例中位54天仍缓解。安全性方面,18例发生≤2级细胞因子释放综合征,1例3级,2例1级神经毒性。
要点
- NS7CAR无需基因编辑即可克服自相残杀,制备出CAR+比例更高、CD8+中央记忆T细胞更多的产物。
- 20例复发/难治T-ALL/LBL中,19例第28天达骨髓MRD阴性CR,9例中5例达髓外CR。
- 安全性以轻度CRS为主(18例≤2级),1例3级CRS,2例1级神经毒性。
核心结论
- NS7CAR-T疗法是T-ALL/LBL安全且高度有效的治疗,但需更多患者和更长随访验证。
研究设计与样本
- 首次人体1期临床试验(NCT04572308),纳入20例复发/难治T细胞急性淋巴细胞白血病(T-ALL,n=14)和T细胞淋巴母细胞淋巴瘤(T-LBL,n=6)患者接受NS7CAR治疗。
主要发现
- 19例患者在第28天达骨髓微小残留病阴性完全缓解,9例中5例达髓外完全缓解。
- 中位随访142.5(范围32-311)天,14例后续接受异基因造血干细胞移植(10例巩固性,4例挽救性),至数据截止无复发。
- 未接受移植的6例中,4例在中位54(范围32-180)天时仍保持完全缓解。
- 18例发生轻度细胞因子释放综合征(≤2级),1例发生3级细胞因子释放综合征,2例发生1级神经毒性。
关键数值与推荐
- 与分选的CD7阴性7CAR T细胞和CD7敲除7CAR T细胞相比,NS7CAR表现出相似或更优的治疗特性,包括更高的CAR+细胞百分比和更高比例的CD8+中央记忆T细胞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需更多患者和更长随访进行验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Derivation of CD7-targeted chimeric antigen receptor (7CAR) T cells often requires genetic manipulations to ablate the CD7 gene or block CD7 cell surface expression. Our novel approach deriving naturally selected 7CAR (NS7CAR) T cells from bulk T cells was able to overcome major fratricide by minimizing accessible CD7 epitopes. The CD7 molecules of NS7CAR T cells were masked or sequestered by the CD7-targeting CAR. Compared with sorted CD7-negative 7CAR T cells and CD7 knocked-out 7CAR T cells, NS7CAR exhibited similar or superior therapeutic properties, including a greater percentage of CAR+ cells and a higher proportion of CD8+ central memory T cells. In our first-in-human phase 1 trial (NCT04572308), 20 patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) (n = 14) and T-cell lymphoblastic lymphoma (T-LBL) (n = 6) were treated with NS7CAR. Nineteen patients achieved minimal residual disease negative complete remission (CR) in the bone marrow (BM) by day 28, and 5 of 9 patients achieved extramedullary CR. With a median follow-up of 142.5 (32-311) days after infusion, 14 patients subsequently received allogeneic hematopoietic stem cell transplant (10 consolidative, 4 salvage) following NS7CAR infusion with no relapses to date. Of the 6 patients who did not receive a transplant, 4 remained in CR at a median time of 54 (32-180) days. Eighteen patients experienced mild cytokine release syndrome (CRS) (grade ≤2), 1 developed grade 3 CRS, and 2 had grade 1 neurotoxicity. These results indicate that NS7CAR-T therapy is a safe and highly effective treatment for T-ALL/LBL. More patients and longer follow-up are needed for validation.
引用
- Lu P, Liu Y, Yang J, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood. 2022. PMID: 35500125. doi:10.1182/blood.2021014498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。